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Background
TG4010 immunotherapy product is a poxvirus (MVA)
coding for MUC1 tumor-associated antigen and interleu-
kin-2. A previous study showed that a normal baseline
level of Triple Positive Activated Lymphocytes (TrPAL,
CD16+CD56+CD69+) might be a predictive biomarker
for TG4010 efficacy in advanced NSCLC [1]. TIME is a
double-blind Phase IIb/III study comparing the combi-
nation of first-line therapy with TG4010 or placebo
(NCT01383148).
Patients and methods
Primary endpoint of the Phase IIb part of the study was to
compare progression-free survival (PFS, according to
RECIST 1.1) between TG4010 and placebo arms using a
Bayesian design, in stage IV NSCLC patients whose tumor
express MUC1. Secondary objectives were response rate,
safety, survival and subgroup analyses according to stratifi-
cation factors and level of TrPAL at baseline. A dynamic
minimization procedure was applied at randomization
for histology, prescription of Bevacizumab, type of che-
motherapy, performance status and center.
Results
217 patients have been enrolled out of which 170 patients
with a normal TrPAL level (pre-determined threshold)
and an analysis of PFS was conducted in this cohort after
137 events of progression were recorded. The hazard
ratio (HR) for PFS is 0.76 (95%CI: 0.54-1.06). This corre-
sponds to a 97.5% Bayesian probability that the true HR
is <1, passing the threshold of 95% needed to consider
the endpoint met in patients with normal TrPAL.
TG4010 related adverse events were limited to mild or
moderate fever and injection site reaction. Analysis in the
75% of patients with the lowest baseline level of TrPAL
(three lowest quartiles, n = 152) shows a HR for PFS of
0.72 (95%CI: 0.50-1.03) consistent with the observation
made in the previous study. Additional pre-planned ana-
lyses by subgroup show that patients with non-squamous
tumors had a statistically significant improvement in PFS
when treated with TG4010 (n = 145, HR = 0.67; CI:
0.46-0.97; p = 0.016) and especially when belonging to
the three lowest quartiles (n = 131, HR = 0.63; 95% CI:
0.42-0.93, p = 0.009). Overall survival data will be pre-
sented at the time of the meeting.
Conclusion
These data confirm TG4010 efficacy and safety profile in
stage IV NSCLC especially in patients with low level of
TrPAL before treatment. They warrant the continuation
of the TIME study with its Phase III part.
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